Kristen Oelschlager Sells 8,587 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) COO Kristen Oelschlager sold 8,587 shares of Castle Biosciences stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $20.71, for a total transaction of $177,836.77. Following the sale, the chief operating officer directly owned 30,460 shares of the company’s stock, valued at $630,826.60. The trade was a 21.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Price Performance

Shares of NASDAQ CSTL opened at $21.12 on Friday. The firm has a market cap of $640.57 million, a P/E ratio of -48.00 and a beta of 1.04. The company has a current ratio of 6.75, a quick ratio of 6.53 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a 1-year low of $14.59 and a 1-year high of $44.28. The business’s 50 day moving average is $21.74 and its 200-day moving average is $29.71.

Castle Biosciences (NASDAQ:CSTL) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.49) earnings per share for the quarter, hitting the consensus estimate of ($0.49). The business had revenue of $84.23 million during the quarter, compared to analysts’ expectations of $79.23 million. Castle Biosciences had a negative return on equity of 2.77% and a negative net margin of 3.78%. Equities research analysts predict that Castle Biosciences, Inc. will post -1.4 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Federated Hermes Inc. acquired a new stake in shares of Castle Biosciences in the 4th quarter valued at approximately $26,000. Kemnay Advisory Services Inc. acquired a new position in Castle Biosciences during the 4th quarter worth approximately $35,000. Jones Financial Companies Lllp increased its position in Castle Biosciences by 10,592.0% during the 1st quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock worth $54,000 after purchasing an additional 2,648 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Castle Biosciences by 26.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,418 shares of the company’s stock valued at $55,000 after purchasing an additional 297 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in Castle Biosciences by 63.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 2,508 shares of the company’s stock valued at $57,000 after purchasing an additional 976 shares during the last quarter. Institutional investors own 92.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on CSTL shares. Canaccord Genuity Group reduced their target price on shares of Castle Biosciences from $50.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, April 20th. Morgan Stanley upgraded shares of Castle Biosciences to a “buy” rating in a research note on Monday, March 2nd. Robert W. Baird cut their price objective on shares of Castle Biosciences from $44.00 to $43.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Weiss Ratings lowered shares of Castle Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 1st. Finally, BTIG Research lowered their target price on shares of Castle Biosciences from $50.00 to $40.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.83.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.